Patents by Inventor Ariel Werman

Ariel Werman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glycan modified soluble receptors and binding protein and their use
    Patent number: 8871723
    Abstract: An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: October 28, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Menachem Rubinstein, Ariel Werman, Ben Alkahe
  • Method for inhibiting release of hepatitis B virus from liver cells
    Patent number: 8293706
    Abstract: The invention relates to the use of the souluble LDL receptor (sLDLR) in viral hepatitis.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: October 23, 2012
    Inventors: Menachem Rubinstein, Ariel Werman, Ben Alkahe
  • GLYCAN MODIFIED SOLUBLE RECEPTORS AND BINDING PROTEIN AND THEIR USE
    Publication number: 20100087363
    Abstract: An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc.
    Type: Application
    Filed: April 30, 2008
    Publication date: April 8, 2010
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Menachem Rubinstein, Ariel Werman, Ben Alkahe